AstraZeneca tired of life? Leaves London and reorganizes global R&D

AstraZeneca's new CEO Pascal Soriot has wasted little time in putting his stamp on the troubled company since joining six months ago. Today saw the firm announcing sweeping changes to its R&D operations around the globe. This comes just three days before the unveiling of Mr Soriot's strategy review conclusions at an investor day in New York.